Filters

See more specimen types...
See more states

Other countries

See more countries

Results: 1 to 20 of 82 (representing 35 labs)

Tests names and labsConditionsGenes and analytesMethods

CentoICU platinum

Centogene AG - the Rare Disease Company
Germany
769514
  • C Sequence analysis of the entire coding region

CentoICU platinum plus

Centogene AG - the Rare Disease Company
Germany
769514
  • C Sequence analysis of the entire coding region

RET, selective sequencing of exons 5, 8, 10, 11 and 13-16

Centogene AG - the Rare Disease Company
Germany
61
  • T Targeted variant analysis

Multiple Endocrine Neoplasia Type 2

Clinical Molecular Genetics Laboratory Johns Hopkins All Children's Hospital
United States
41
  • E Sequence analysis of select exons

Multiple endocrine neoplasia type IIA

Centogene AG - the Rare Disease Company
Germany
11
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

Multiple Endoctine Neoplasia Type 2 (RET)

Molecular Genetics Laboratory London Health Sciences Centre
Canada
51
  • D Deletion/duplication analysis
  • E Sequence analysis of select exons
  • C Sequence analysis of the entire coding region

Hereditary Thyroid Cancer - RET Gene Analysis

GeneKor MSA
Greece
41
  • E Sequence analysis of select exons

RET. Complete sequencing

Instituto de Medicina Genomica
Spain
11
  • C Sequence analysis of the entire coding region

RET. Sequencing of the exons 13, 14, 15 and 16

Instituto de Medicina Genomica
Spain
11
  • E Sequence analysis of select exons

RET. Sequencing of the exons 10 and 11

Instituto de Medicina Genomica
Spain
11
  • E Sequence analysis of select exons

MitoMet®Plus aCGH Analysis

Baylor Genetics
United States
845637
  • D Deletion/duplication analysis

Multiple Endocrine Neoplasia Type 2A (MEN2A) and Familial Medullary Thyroid Carcinoma (FMTC) via the RET Gene - Tier 1

PreventionGenetics
United States
21
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis

Multiple Endocrine Neoplasia Type 2A (MEN2A) and Familial Medullary Thyroid Carcinoma (FMTC) via the RET Gene - Tier 2

PreventionGenetics
United States
21
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis

Sequencing of risk exons of the RET proto-oncogene (exons 10, 11, 13, 14, 15, 16)

Department of Molecular Endocrinology Institute of Endocrinology
Czech Republic
51
  • E Sequence analysis of select exons

Multiple endocrine neoplasia, type 2

Labor Dr. Wisplinghoff
Germany
21
  • C Sequence analysis of the entire coding region

Hyperparathyroidism Spotlight Panel

Courtagen Diagnostics Laboratory Courtagen Life Sciences
United States
136
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

Waardenburg Syndrome panel

Molecular Vision Laboratory
United States
197
  • C Sequence analysis of the entire coding region

Invitae Pediatric Solid Tumors Panel

Invitae
United States
9148
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

Multiple Endocrine Neoplasia Type 2: RET gene sequence analysis

GENETAQ Molecular Genetics Centre and Diagnosis of Rare Diseases
Spain
31
  • C Sequence analysis of the entire coding region

Multiple endocrine Neoplasia type 2 (MEN2): RET gene sequence analysis (remaining exons: 1-9, 12, 17-20)

GENETAQ Molecular Genetics Centre and Diagnosis of Rare Diseases
Spain
31
  • E Sequence analysis of select exons

Results: 1 to 20 of 82

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.

Support Center